Hyloris Pharmaceuticals Future Growth
Future criteria checks 2/6
Hyloris Pharmaceuticals's earnings are forecast to decline at 13.6% per annum while its annual revenue is expected to grow at 70.3% per year. EPS is expected to decline by 4.5% per annum.
Key information
-13.6%
Earnings growth rate
-4.5%
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | 70.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 33 | -19 | -45 | -19 | 2 |
| 12/31/2025 | 11 | -19 | -24 | -18 | 2 |
| 12/31/2024 | 7 | -16 | -15 | -15 | 2 |
| 6/30/2024 | 7 | -13 | -13 | -12 | N/A |
| 3/31/2024 | 6 | -14 | -13 | -12 | N/A |
| 12/31/2023 | 4 | -15 | -14 | -13 | N/A |
| 9/30/2023 | 3 | -14 | -13 | -12 | N/A |
| 6/30/2023 | 3 | -13 | -12 | -11 | N/A |
| 3/31/2023 | 3 | -12 | -13 | -12 | N/A |
| 12/31/2022 | 2 | -12 | -14 | -13 | N/A |
| 9/30/2022 | 3 | -10 | -12 | -11 | N/A |
| 6/30/2022 | 3 | -8 | -9 | -8 | N/A |
| 3/31/2022 | 3 | -10 | -11 | -10 | N/A |
| 12/31/2021 | 3 | -12 | -12 | -11 | N/A |
| 9/30/2021 | 2 | -12 | -13 | -13 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -7 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -5 | -5 | N/A |
| 9/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 6/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 3/31/2020 | 0 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -5 | N/A |
| 12/31/2018 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2017 | 0 | -4 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0AB6 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0AB6 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0AB6 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0AB6's revenue (70.3% per year) is forecast to grow faster than the UK market (3.6% per year).
High Growth Revenue: 0AB6's revenue (70.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0AB6's Return on Equity is forecast to be high in 3 years time